A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
一项双盲、随机对照试验，旨在评估在二甲双胍和二肽基肽酶-4抑制剂治疗血糖控制不佳的2型糖尿病患者中，加用0.25或0.5 mg洛贝格列酮的降血糖效果和安全性：REFIND研究
期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.14766
Ryang, Soree; Kim, Sang Soo; Bae, Ji Cheol; Han, Ji Min; Kwon, Su Kyoung; Kim, Young Il; Nam-Goong, Il Seong; Kim, Eun Sook; Kim, Mi-Kyung; Lee, Chang Won; Yoo, Soyeon; Koh, Gwanpyo; Kwon, Min Jeong; Park, Jeong Hyun; Kim, In Joo
